• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal.

作者信息

Yang Tengfei, Zhao Bo

机构信息

Department of Social Services, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning Province, China.

Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China.

出版信息

Crit Care. 2024 Nov 19;28(1):373. doi: 10.1186/s13054-024-05157-x.

DOI:10.1186/s13054-024-05157-x
PMID:39563439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11577887/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c4a/11577887/d2e01f433810/13054_2024_5157_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c4a/11577887/739b47bec287/13054_2024_5157_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c4a/11577887/d2e01f433810/13054_2024_5157_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c4a/11577887/739b47bec287/13054_2024_5157_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c4a/11577887/d2e01f433810/13054_2024_5157_Fig2_HTML.jpg

相似文献

1
The effects between andexanet alpha and four-factor prothrombin complex concentrate on DOACs anticoagulation reversal.andexanet alpha与四因子凝血酶原复合物浓缩物对直接口服抗凝剂（DOACs）抗凝逆转的影响。
Crit Care. 2024 Nov 19;28(1):373. doi: 10.1186/s13054-024-05157-x.
2
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis.依达赛珠单抗 α 对比四种因子的凝血酶原复合物在 DOACs 抗凝逆转中的应用：一项更新的系统评价和荟萃分析。
Crit Care. 2024 Jul 5;28(1):221. doi: 10.1186/s13054-024-05014-x.
3
Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.Andexanet Alfa 或凝血酶原复合物浓缩物逆转急性大出血时的因子 Xa 抑制剂：系统评价和荟萃分析。
Crit Care Med. 2021 Oct 1;49(10):e1025-e1036. doi: 10.1097/CCM.0000000000005059.
4
Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.回顾性分析 Andexanet Alfa 与 4 因子凝血酶原复合物浓缩物在逆转 DOAC 相关颅内出血中的作用。
J Thromb Thrombolysis. 2023 Jan;55(1):149-155. doi: 10.1007/s11239-022-02715-4. Epub 2022 Nov 10.
5
The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.依达赛珠单抗与 4 因子凝血酶原复合物在危及生命的颅内出血中的应用比较。
Blood Coagul Fibrinolysis. 2024 Apr 1;35(3):94-100. doi: 10.1097/MBC.0000000000001279. Epub 2024 Feb 12.
6
Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.使用包括andexanet alfa和四因子凝血酶原复合物浓缩物在内的逆转或替代药物对口服Xa因子抑制剂相关出血进行的真实世界管理：一项多中心研究。
Future Cardiol. 2021 Jan;17(1):127-135. doi: 10.2217/fca-2020-0073. Epub 2020 Jul 3.
7
Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.体外研究瑞伐沙班抗凝作用逆转中andexanet alfa 与凝血酶原复合物浓缩物的对比分析
Br J Anaesth. 2024 Feb;132(2):251-259. doi: 10.1016/j.bja.2023.10.018. Epub 2023 Nov 28.
8
Andexanet alfa or prothrombin complex concentrate for acute reversal of oral factor Xa inhibitors: monitoring of antidote effects.用于口服Xa因子抑制剂急性逆转的andexanet alfa或凝血酶原复合物浓缩物：解毒剂效果监测。
Br J Anaesth. 2024 Feb;132(2):215-217. doi: 10.1016/j.bja.2023.11.028. Epub 2023 Dec 8.
9
Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).新型直接口服抗凝药物（DOACs）的逆转
Cardiovasc Hematol Agents Med Chem. 2017;14(2):76-81. doi: 10.2174/1871525714666160524144359.
10
In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.直接凝血因子Xa抑制剂的体外逆转：阿哌沙班与凝血酶原复合物浓缩剂Cofact和百瑞维宁/凝血因子复合物Kcentra的直接比较
Res Pract Thromb Haemost. 2022 Aug 1;6(5):e12775. doi: 10.1002/rth2.12775. eCollection 2022 Jul.

本文引用的文献

1
Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis.依达赛珠单抗 α 对比四种因子的凝血酶原复合物在 DOACs 抗凝逆转中的应用：一项更新的系统评价和荟萃分析。
Crit Care. 2024 Jul 5;28(1):221. doi: 10.1186/s13054-024-05014-x.
2
The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.依达赛珠单抗与 4 因子凝血酶原复合物在危及生命的颅内出血中的应用比较。
Blood Coagul Fibrinolysis. 2024 Apr 1;35(3):94-100. doi: 10.1097/MBC.0000000000001279. Epub 2024 Feb 12.
3
Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
依达赛珠单抗对比非特异性治疗用于服用因子 Xa 抑制剂的颅内出血患者：ANNEXA-4 和 TICH-NOAC 的个体患者数据分析。
Int J Stroke. 2024 Jun;19(5):506-514. doi: 10.1177/17474930241230209. Epub 2024 Mar 8.
4
The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.依达赛珠单抗和 4 因子凝血酶原复合物在颅内出血中的应用。
Am J Emerg Med. 2023 Feb;64:74-77. doi: 10.1016/j.ajem.2022.11.023. Epub 2022 Nov 18.
5
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.依诺肝素相关非外伤性颅内出血患者在 ANNEXA-4 试验内接受治疗与真实世界常规治疗的血肿扩大和临床结局。
Stroke. 2022 Feb;53(2):532-543. doi: 10.1161/STROKEAHA.121.034572. Epub 2021 Oct 14.
6
Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.依达赛珠单抗与 4 因子凝血酶原复合物用于逆转 Xa 因子抑制剂相关出血的回顾性比较
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039020. doi: 10.1177/10760296211039020.
7
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.andexanet alfa和四因子凝血酶原复合物浓缩剂用于逆转阿哌沙班和利伐沙班在颅内出血患者中的作用。
J Thromb Thrombolysis. 2022 Jan;53(1):167-175. doi: 10.1007/s11239-021-02495-3. Epub 2021 Jun 8.